T. Braun and P. Fenaux, Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.327-363, 2013.
DOI : 10.1016/j.beha.2013.09.003

A. Mekinian, T. Braun, O. Decaux, G. Falgarone, E. Toussirot et al., Inflammatory Arthritis in Patients With Myelodysplastic Syndromes, Medicine, vol.93, issue.1, pp.1-10, 2014.
DOI : 10.1097/MD.0000000000000011
URL : https://hal.archives-ouvertes.fr/hal-01064616

D. Albert and C. Burns, Rheumatologic Manifestations in Myelodysplastic Syndrome, Journal of Clinical Rheumatology, vol.18, issue.3, pp.148-50, 2012.
DOI : 10.1097/RHU.0b013e31825003e4

L. Prat, J. Bouaziz, D. Wallach, M. Vignon?pennamen, and M. Bagot, Neutrophilic dermatoses as systemic diseases, Clinics in Dermatology, vol.32, issue.3, pp.376-88, 2014.
DOI : 10.1016/j.clindermatol.2013.11.004

P. Fenaux, G. Mufti, E. Hellstrom?lindberg, V. Santini, C. Finelli et al., Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, The Lancet Oncology, vol.10, issue.3, pp.223-255, 2009.
DOI : 10.1016/S1470-2045(09)70003-8

R. Costa, H. Abdulhaq, B. Haq, R. Shadduck, J. Latsko et al., Activity of azacitidine in chronic myelomonocytic leukemia, Cancer, vol.88, issue.suppl 1, pp.2690-2696, 2011.
DOI : 10.1002/cncr.25759

L. Fianchi, M. Criscuolo, M. Breccia, L. Maurillo, F. Salvi et al., High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study, Leukemia & Lymphoma, vol.89, issue.3, pp.658-61, 2013.
DOI : 10.1038/leu.2011.170

K. Raj, A. Ho, J. Creamer, A. Vivier, J. Salisbury et al., Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine, British Journal of Dermatology, vol.163, issue.5, pp.1039-1080, 2007.
DOI : 10.1016/S1521-6616(03)00206-7

A. Ustwani, O. Francis, J. Wallace, P. Ambrus, J. Wetzler et al., Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells, Leukemia Research, vol.35, issue.5, pp.35-41, 2011.
DOI : 10.1016/j.leukres.2010.12.015

S. Pilorge, L. Doleris, F. Dreyfus, and S. Park, The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases, British Journal of Haematology, vol.73, issue.5, 2011.
DOI : 10.1111/j.1365-2141.2010.08557.x

J. Frietsch, S. Dornaus, T. Neumann, S. Scholl, V. Schmidt et al., Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review, European Journal of Haematology, vol.149, issue.Suppl 1, pp.247-59, 2014.
DOI : 10.1111/ejh.12311

H. Tanaka, N. Shimizu, E. Tougasaki, C. Kawajiri, S. Hashimoto et al., Successful treatment by azacitidine therapy of intestinal Beh??et???s disease associated with myelodysplastic syndrome, International Journal of Hematology, vol.10, issue.3, pp.520-524, 2013.
DOI : 10.1007/s12185-013-1316-x

A. Mekinian, E. Grignano, T. Braun, O. Decaux, E. Liozon et al., Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study, Rheumatology, vol.55, issue.2, 2015.
DOI : 10.1093/rheumatology/kev294
URL : https://hal.archives-ouvertes.fr/hal-01299293

E. Gyan, V. Andrieu, A. Sanna, A. Caille, J. Schemenau et al., Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis, British Journal of Haematology, vol.21, issue.5, 2016.
DOI : 10.1111/bjh.13902
URL : https://hal.archives-ouvertes.fr/hal-01453321

A. Wanquet, T. Prebet, C. Berthon, M. Sebert, C. Roux et al., Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities, American Journal of Hematology, vol.116, issue.Suppl 1, pp.859-63, 2015.
DOI : 10.1002/ajh.24099

G. Damaj, M. Mohty, R. M. Michallet, M. Chevallier, P. Beguin et al., Upfront allogeneic stem cell transplantation after reduced?intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société